You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Checkpoint kinase 1 CHK1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)

Not yet recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • (no location specified)
Aug 1, 2023

Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Lymphoma, Mantle-Cell
  • (no location specified)
Dec 22, 2022

NSCLC, Non-Small Cell Lung Adenocarcinoma, Non-Small Cell Squamous Lung Cancer Trial in Grand Rapids, San Antonio, Fairfax

Recruiting
  • Non-small Cell Lung Cancer
  • +10 more
  • Grand Rapids, Michigan
  • +2 more
Apr 25, 2023

Cervical Cancer, Cervical Carcinoma Trial in Guangzhou (Zimberelimab, Lenvatinib)

Not yet recruiting
  • Cervical Cancer
  • Cervical Carcinoma
  • Guangzhou, China
    Sun Yat-sen University Cancer Cetntre
Apr 9, 2023

Advanced Cancers Trial in Boston (LY2606368)

Active, not recruiting
Has Results
  • Advanced Cancers
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 18, 2022

PD-1 Checkpoint Blockade Using Deep Learning Analysis of Imaging

Completed
  • Non-small Cell Lung Cancer (NSCLC)
    • Nîmes, France
      Jean-Paul BEREGI
    Jan 25, 2023

    Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL) Trial in United Kingdom (SRA737)

    Completed
    Has Results
    • Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
    • Sutton, London, United Kingdom
    • +14 more
    Mar 9, 2022

    Healthy Volunteers Trial in Cincinnati (CHK336, Placebo)

    Recruiting
    • Healthy Volunteers
    • Cincinnati, Ohio
      Medpace Clinical Pharmacology Unit
    Jan 27, 2023

    Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

    Completed
    • Gastrointestinal Tumor
    • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
    • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
    • Hangzhou, China
      Zhejiang Hospital
    Sep 1, 2023

    Alopecia Areata Trial in Sohag (Janus Kinase 1 and 2)

    Recruiting
    • Alopecia Areata
    • Janus Kinase 1 and 2
    • Sohag, Egypt
      Sohag University hospitals
    May 12, 2023

    NSCLC Associated With Leptomeningeal Metastases Trial (Tislelizumab, pemetrexed)

    Not yet recruiting
    • NSCLC Associated With Leptomeningeal Metastases
    • Tislelizumab, pemetrexed
    • (no location specified)
    Nov 21, 2023

    Development ofEORTC Immune Checkpoint Inhibitor-specific Quality

    Recruiting
    • Cancer
    • +2 more
      • Paris, France
        Institut Curie
      Nov 2, 2022

      Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

      Active, not recruiting
      • Neurofibromatosis 1
      • Neurofibroma Plexiform
      • Shanghai, China
      • +1 more
      Jan 13, 2023

      Solid Tumor Trial in Boston (Prexasertib, Olaparib)

      Completed
      • Solid Tumor
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      Sep 1, 2021

      Pre-transplant ICI Exposure and Post-transplant Graft Rejection

      Recruiting
      • Graft Rejection
      • +3 more
      • Immune checkpoint inhibitor
      • Guangzhou, Guangdong, China
        Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun
      Jun 21, 2023

      Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemo Effect Trial in Guangzhou (PD-1 Immune Checkpoint

      Active, not recruiting
      • Recurrent Nasopharyngeal Carcinoma
      • +2 more
      • PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
      • Guangzhou, Guangdong, China
        Yanqun Xiang
      Sep 5, 2022

      Cancer Trial in Boston (LY3300054, Prexasertib)

      Completed
      • Cancer
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      Apr 13, 2021

      Fibrolamellar Hepatocellular Carcinoma Trial in Tuebingen (Fusion-VAC-XS15)

      Not yet recruiting
      • Fibrolamellar Hepatocellular Carcinoma
      • Tuebingen, Baden-Würtemberg, Germany
        University Hospital Tuebingen
      Jun 29, 2023

      Locally Advanced Pancreatic Adenocarcinoma Trial in Houston (SD-101, pebrolizumab)

      Recruiting
      • Locally Advanced Pancreatic Adenocarcinoma
      • Houston, Texas
        MD Anderson Cancer Center
      Nov 18, 2022

      Gut and Tumor Microbiome in Advanced ER-positive and

      Not yet recruiting
      • Breast Cancer
      • Melanoma
      • Observation
      • (no location specified)
      Nov 6, 2023

      Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

      Not yet recruiting
      • Metastatic Pancreatic Cancer
      • Durvalumab
      • Rintatolimod
      • Rotterdam, Zuid-Holland, Netherlands
        Erasmus MC
      Jun 23, 2023

      Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma

      Not yet recruiting
      • Anatomic Stage III Breast Cancer AJCC v8
      • +4 more
      • Biopsy
      • +5 more
      • Buffalo, New York
        Roswell Park Cancer Institute
      Feb 14, 2023

      Solid Tumors, Adult Trial in Kaunas (NECVAX-NEO1)

      Recruiting
      • Solid Tumors, Adult
      • NECVAX-NEO1
      • Kaunas, Lithuania
        Elona Juozaityte
      May 16, 2022

      Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

      Recruiting
      • Neurofibromatosis 1
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 20, 2023

      Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

      Enrolling by invitation
      • Hepatocellular Carcinoma Non-resectable
      • +3 more
      • lenvatinib + sindilimab/carrelizumab
      • TACE
      • Chengdu, Sichuan, China
        West China Hospital of Sichuan University
      May 23, 2022